Arcus Biosciences Inc (NYSE:RCUS)
$ 16 0.16 (1.01%) Market Cap: 1.46 Bil Enterprise Value: 456.70 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 75/100

Arcus Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 04:20PM GMT
Release Date Price: $20.72 (-4.34%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thank you so much for joining us for the presentation with Arcus. We're really pleased to have Terry Rosen, CEO; and Jennifer Jarrett, COO. With that, Terry, I'm going to turn it over to you. Just given you've got a ton of data reads this year, maybe you could just put it in context and then we can jump in.

Terry J. Rosen
Arcus Biosciences, Inc. - Co-Founder, Chairman & CEO

Sure. Thanks, Salveen. So Arcus has been around since 2015. And I think big difference between how we ended 2021 and how we'll end 2022 and maybe I'll level set where we are in that context. So as we ended 2021, we had one registrational trial. And as everybody knows, we have 6 molecules in the clinic: 2 in the ATP adenosine pathway, 2 anti-TIGIT, our anti-PD-1 and our most recent, our HIF-2 inhibitor, AB521.

With the data that we generated in ARC-7 in our third interim analysis, that totally reinforced our plans for registrational studies around the anti-TIGIT/zimberelimab

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot